Zimmer Biomet Stock (ZBH)

XNYS Alert Compare

Health Care · Fundamental analysis

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Zimmer Biomet is a US medical technology maker. Its focus is artificial knee and hip joints, plus products for shoulders, spine and sports medicine and surgical robots. Customers are hospitals worldwide. As of Oct 11, 2026

Fact sheet (from the annual report) Orthopedic and surgical supplies · Warsaw, USA

Zimmer Biomet designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities and trauma products, bone cement, surgical products and digital and robotic technologies. The products are used for diseases and injuries of bones, joints and soft tissue, for example in knee and hip replacement. Its main customers are orthopedic surgeons, neurosurgeons and other specialists, healthcare facilities, stocking distributors and purchasing organizations. Sales run directly to hospitals and ambulatory surgery centers or through stocking and specialty distributors; for direct customers and some distributors, the goods are generally held on consignment with representatives or customers. The operating segments are organized regionally into Americas, Europe with the Middle East and Africa, and Asia Pacific; Americas covers mainly the US market.

Automatically summarized from SEC annual report (10-K, filed Feb 20, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −0.4%
  • 7 days −2.0%
  • 30 days +6.6%
  • 1 year +13.5%
Day range (last trading day)
−0.3%Price at 9% of the range+2.7%
52-week range
−21.7%Price at 66% of the range+11.3%
Distance from the all-time high
−42.3%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Fundamentals · Analysis method

Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis

Fundamental analysis

Zimmer Biomet · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 20, 2026.

For you first Dividend

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 7.7x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
0.0%
dividend per share, average per year
Coverage by free cash flow
7.7x
covered from 1.0x

For you first Valuation

The P/E is below its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
4 of 5
criteria with data met
Revenue per year (5 y)
+3.2%
EPS per year (3 y)
+47.8%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
5 of 8
criteria with data met
Net margin
8.6%
Cash flow ÷ profit
2.41x
backed from 1.0 · 3 years: 1.81x

For you first Trading

The overview of this stock shows the trend by timeframe.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 5 of 8 met

  • met: Gross margin above 40% 69.7%
  • not met: Operating margin above 15% 13.3%
  • not met: Net margin above 10% 8.6%
  • not met: Return on equity above 15% 5.6%
  • met: Free cash flow margin above 10% 17.9%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 55.0%
Gross margin

69.7% Fiscal year 2025

Rank 82 of 100: higher than 82% of 370 peers (All). strong.

Rank 72 of 100: higher than 72% of 49 peers (Sector). strong.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Operating margin

13.3% Fiscal year 2025

Rank 44 of 100: higher than 44% of 470 peers (All). medium.

Rank 38 of 100: higher than 38% of 54 peers (Sector). medium.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

8.6% Fiscal year 2025

Rank 37 of 100: higher than 37% of 584 peers (All). medium.

Rank 36 of 100: higher than 36% of 63 peers (Sector). medium.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

5.6% Fiscal year 2025

Rank 22 of 100: higher than 22% of 544 peers (All). weak.

Rank 18 of 100: higher than 18% of 54 peers (Sector). weak.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

3.1% Fiscal year 2025 (total assets at year end)

Rank 35 of 100: higher than 35% of 594 peers (All). medium.

Rank 23 of 100: higher than 23% of 63 peers (Sector). weak.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

55.0% Fiscal year 2025

Rank 78 of 100: higher than 78% of 595 peers (All). strong.

Rank 69 of 100: higher than 69% of 63 peers (Sector). strong.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

17.9% Fiscal year 2025

Rank 70 of 100: higher than 70% of 465 peers (All). strong.

Rank 65 of 100: higher than 65% of 61 peers (Sector). medium.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

1.5B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 4 of 5 met · 2 without data

  • met: Over 3 years, revenue grew by more than 5% per year +5.9%
  • not met: Over 5 years, revenue grew by more than 5% per year +3.2%
  • no data: Over 10 years, revenue grew by more than 5% per year no comparable figures over 10 years
  • met: Over 3 years, EPS grew by more than 5% per year +47.8%
  • no data: Over 5 years, EPS grew by more than 5% per year not computable (loss in the first year, or figures missing)
  • met: Revenue rose in at least 4 of the last 5 fiscal years 4 of 5
  • met: Revenue rose in the last fiscal year +7.2%
Revenue growth 3 years

+5.9% per year

Rank 49 of 100: higher than 49% of 578 peers (All). medium.

Rank 57 of 100: higher than 57% of 62 peers (Sector). medium.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+3.2% per year

Rank 17 of 100: higher than 17% of 549 peers (All). weak.

Rank 14 of 100: higher than 14% of 60 peers (Sector). weak.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

EPS growth 3 years

+47.8% per year

Rank 93 of 100: higher than 93% of 437 peers (All). strong.

Rank 88 of 100: higher than 88% of 54 peers (Sector). strong.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+16.5% per year

Rank 80 of 100: higher than 80% of 375 peers (All). strong.

Rank 77 of 100: higher than 77% of 46 peers (Sector). strong.

Median Health Care: +9.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 6 of 7 met

  • met: Pays a dividend 0.96 USD
  • met: Payout ratio at most 60% of earnings 27%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • not met: Dividend per share higher than 5 years ago 0.0%
  • met: Free cash flow per share covers the dividend 7.7x
  • met: Dividends paid over the last 5 years covered by free cash flow 15% of free cash flow
Payout ratio

27% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

0.0% per year

Rank 6 of 100: higher than 6% of 321 peers (All). weak.

Rank 8 of 100: higher than 8% of 31 peers (Sector). weak.

Median Health Care: +6.6%

Growth of the dividend per share per year.

Free cash flow coverage

7.7x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 5 of 6 met

  • not met: Piotroski F-Score at least 7 of 9 6 of 9
  • met: Long-term debt no higher than equity 0.55
  • met: Current assets cover current liabilities 1.98
  • met: Positive equity 12.7B USD
  • met: In 5 years, share count up by at most 5% −4.0%
  • met: Free cash flow positive in the last fiscal year 1.5B USD
Piotroski F-Score

6 of 9 Fiscal year 2025

Rank 45 of 100: higher than 45% of 310 peers (All). medium.

Rank 38 of 100: higher than 38% of 47 peers (Sector). medium.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.55 at fiscal year end

Rank 58 of 100: lower than 58% of 486 peers (All). medium.

Rank 59 of 100: lower than 59% of 50 peers (Sector). medium.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.98 at fiscal year end

Rank 73 of 100: higher than 73% of 513 peers (All). strong.

Rank 66 of 100: higher than 66% of 63 peers (Sector). medium.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−4.0% in 5 years

Rank 54 of 100: lower than 54% of 507 peers (All). medium.

Rank 47 of 100: lower than 47% of 59 peers (Sector). medium.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • not met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+3.2% per year), more slowly than the sector median.
  • Light yellow: Net margin 8.6%, below the sector median (13.9%).
  • Light green: Debt not higher than usual in the sector.
  • Light red: Profit in 8 of 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 7.7B USD · Net income 305.9M USD · Net margin 4.0%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 7.8B USD · Net income 1.8B USD · Net margin 23.2%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 7.9B USD · Net income −379.2M USD · Net margin −4.8%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 8.0B USD · Net income 1.1B USD · Net margin 14.2%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 7.0B USD · Net income −138.9M USD · Net margin −2.0%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 7.8B USD · Net income 401.6M USD · Net margin 5.1%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 6.9B USD · Net income 231.4M USD · Net margin 3.3%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 7.4B USD · Net income 1.0B USD · Net margin 13.8%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 7.7B USD · Net income 903.8M USD · Net margin 11.8%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 8.2B USD · Net income 705.1M USD · Net margin 8.6%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 8.2B USD · Net income 705.1M USD · Net margin 8.6%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 +3.1% vs. the same quarter a year earlier; grown for 15 quarters in a row.

Revenue 12 months vs. prior 12
+7.0%
12 months: 8.6B USD · Fiscal year 2025: +7.2%
Net margin 12 months
9.0%
Fiscal year 2025: 8.6%
Free cash flow margin 12 months
19.2%
Fiscal year 2025: 17.9%
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 8.2B USD + year to date to Sep 30, 2026 6.3B USD − same period a year earlier to Sep 30, 2025 6.0B USD = 8.6B USD
  • Net income: fiscal year to Dec 31, 2025 705.1M USD + year to date to Sep 30, 2026 628.1M USD − same period a year earlier to Sep 30, 2025 565.8M USD = 767.4M USD
  • Operating cash flow: fiscal year to Dec 31, 2025 1.7B USD + year to date to Sep 30, 2026 1.4B USD − same period a year earlier to Sep 30, 2025 1.2B USD = 1.9B USD
  • Capital expenditure: fiscal year to Dec 31, 2025 224.5M USD + year to date to Sep 30, 2026 166.3M USD − same period a year earlier to Sep 30, 2025 149.7M USD = 241.1M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 262.1B+3.1%191.6M9.3%
Apr–Jun 262.2B+4.8%198.3M9.1%
Jan–Mar 262.1B+9.3%238.1M11.4%
Oct–Dec 25*2.2B+10.9%139.3M6.2%
Jul–Sep 252.0B+9.7%230.9M11.5%
Apr–Jun 252.1B+7.0%152.8M7.4%
Jan–Mar 251.9B+1.1%182.0M9.5%
Oct–Dec 24*2.0B+4.3%239.5M11.8%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 30, 2026, filed on Nov 4, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is backed by cash; interest is covered.

Cash flow ÷ profit
2.41x
backed from 1.0 · 3 years: 1.81x
Interest coverage
3.8x
well covered from 5 · net interest expense · 3 years: 5.1x
Tax rate
15.1%
for information only · 3 years: 10.2%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 1.7B USD ÷ Net income 705.1M USD = 2.41x
  • Operating income 1.1B USD ÷ net interest expense 292.8M USD = 3.8x
  • Taxes 125.7M USD ÷ profit before tax 830.8M USD = 15.1%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20252.41x3.8x15.1%
20241.66x5.9x12.7%
20231.54x6.4x4.0%
20225.86x4.2x27.8%
20213.73x3.7x3.9%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years 2 loss years; 2 years with lower revenue across 9 years with a prior-year figure.

Loss years
2 of 10
net income below zero
Years with lower revenue
2 of 9
revenue below the prior year
Net margin range
28.0 percentage points
from −4.8% to 23.2%
Net margin by fiscal year · ▾ revenue below the prior year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+7.2%8.6%
2024+3.8%11.8%
2023+6.5%13.8%
2022−11.4%3.3%
2021+11.6%5.1%
2020−12.0%−2.0%
2019+0.6%14.2%
2018+1.7%−4.8%
2017+1.8%23.2%
2016–4.0%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 69.7 USD gross profit, 13.3 USD operating income and 8.6 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue8.2B USD100.0%
Gross profit5.7B USD69.7%
Cost of revenue2.5B USD30.3%
Operating income1.1B USD13.3%
Research & development458.5M USD5.6%
Other operating expenses4.2B USD50.8%
Net income705.1M USD8.6%
Taxes125.7M USD1.5%
Interest & other267.3M USD3.2%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin rose in 5 years from −1.2% to 13.3%.

Gross marginOperating marginNet margin
  1. Fiscal year 2016: Gross margin 68.9% · Operating margin 10.8% · Net margin 4.0%
  2. Fiscal year 2017: Gross margin not available · Operating margin 10.4% · Net margin 23.2%
  3. Fiscal year 2018: Gross margin not available · Operating margin 0.4% · Net margin −4.8%
  4. Fiscal year 2019: Gross margin 71.8% · Operating margin 14.3% · Net margin 14.2%
  5. Fiscal year 2020: Gross margin 69.7% · Operating margin −1.2% · Net margin −2.0%
  6. Fiscal year 2021: Gross margin not available · Operating margin 10.0% · Net margin 5.1%
  7. Fiscal year 2022: Gross margin not available · Operating margin 10.0% · Net margin 3.3%
  8. Fiscal year 2023: Gross margin 71.8% · Operating margin 17.3% · Net margin 13.8%
  9. Fiscal year 2024: Gross margin 71.5% · Operating margin 16.7% · Net margin 11.8%
  10. Fiscal year 2025: Gross margin 69.7% · Operating margin 13.3% · Net margin 8.6%

Returns

Return on equity rose in 5 years from −1.1% to 5.6%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 3.2% · Return on assets 1.1%
  2. Fiscal year 2017: Return on equity 15.5% · Return on assets 7.0%
  3. Fiscal year 2018: Return on equity −3.4% · Return on assets −1.6%
  4. Fiscal year 2019: Return on equity 9.1% · Return on assets 4.6%
  5. Fiscal year 2020: Return on equity −1.1% · Return on assets −0.6%
  6. Fiscal year 2021: Return on equity 3.2% · Return on assets 1.7%
  7. Fiscal year 2022: Return on equity 1.9% · Return on assets 1.1%
  8. Fiscal year 2023: Return on equity 8.2% · Return on assets 4.8%
  9. Fiscal year 2024: Return on equity 7.2% · Return on assets 4.2%
  10. Fiscal year 2025: Return on equity 5.6% · Return on assets 3.1%

Equity and long-term debt

The equity ratio rose in 5 years from 49.9% to 55.0%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 9.7B USD · Long-term debt 10.7B USD
  2. Fiscal year 2017: Equity 11.7B USD · Long-term debt 8.9B USD
  3. Fiscal year 2018: Equity 11.3B USD · Long-term debt 8.4B USD
  4. Fiscal year 2019: Equity 12.4B USD · Long-term debt 6.7B USD
  5. Fiscal year 2020: Equity 12.2B USD · Long-term debt 7.6B USD
  6. Fiscal year 2021: Equity 12.7B USD · Long-term debt 5.5B USD
  7. Fiscal year 2022: Equity 12.0B USD · Long-term debt 5.2B USD
  8. Fiscal year 2023: Equity 12.5B USD · Long-term debt 4.9B USD
  9. Fiscal year 2024: Equity 12.5B USD · Long-term debt 5.3B USD
  10. Fiscal year 2025: Equity 12.7B USD · Long-term debt 6.9B USD

Liquidity (current ratio)

The current ratio stayed roughly the same in 5 years (1.98).

Current ratio
  1. Fiscal year 2016: Current ratio 1.96
  2. Fiscal year 2017: Current ratio 1.50
  3. Fiscal year 2018: Current ratio 1.83
  4. Fiscal year 2019: Current ratio 1.37
  5. Fiscal year 2020: Current ratio 1.99
  6. Fiscal year 2021: Current ratio 1.41
  7. Fiscal year 2022: Current ratio 1.88
  8. Fiscal year 2023: Current ratio 1.61
  9. Fiscal year 2024: Current ratio 1.91
  10. Fiscal year 2025: Current ratio 1.98

Cash flow

Free cash flow rose in 5 years from 1.1B USD to 1.5B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 1.6B USD · Capital expenditure 184.7M USD · Free cash flow 1.4B USD
  2. Fiscal year 2017: Operating cash flow 1.6B USD · Capital expenditure 156.0M USD · Free cash flow 1.4B USD
  3. Fiscal year 2018: Operating cash flow 1.7B USD · Capital expenditure 162.7M USD · Free cash flow 1.6B USD
  4. Fiscal year 2019: Operating cash flow 1.6B USD · Capital expenditure 207.1M USD · Free cash flow 1.4B USD
  5. Fiscal year 2020: Operating cash flow 1.2B USD · Capital expenditure 117.5M USD · Free cash flow 1.1B USD
  6. Fiscal year 2021: Operating cash flow 1.5B USD · Capital expenditure 172.0M USD · Free cash flow 1.3B USD
  7. Fiscal year 2022: Operating cash flow 1.4B USD · Capital expenditure 187.9M USD · Free cash flow 1.2B USD
  8. Fiscal year 2023: Operating cash flow 1.6B USD · Capital expenditure 291.1M USD · Free cash flow 1.3B USD
  9. Fiscal year 2024: Operating cash flow 1.5B USD · Capital expenditure 203.8M USD · Free cash flow 1.3B USD
  10. Fiscal year 2025: Operating cash flow 1.7B USD · Capital expenditure 224.5M USD · Free cash flow 1.5B USD

Share count

The share count fell in 5 years by 4.0% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 202.4M
  2. Fiscal year 2017: Diluted share count 203.7M
  3. Fiscal year 2018: Diluted share count 203.5M
  4. Fiscal year 2019: Diluted share count 206.7M
  5. Fiscal year 2020: Diluted share count 207.0M
  6. Fiscal year 2021: Diluted share count 210.4M
  7. Fiscal year 2022: Diluted share count 210.3M
  8. Fiscal year 2023: Diluted share count 209.7M
  9. Fiscal year 2024: Diluted share count 203.9M
  10. Fiscal year 2025: Diluted share count 198.7M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Earnings per share

Earnings per share rose in 5 years from −0.67 USD to 3.55 USD.

ZBH USD per share
  1. Fiscal year 2016: ZBH 1.51 USD
  2. Fiscal year 2017: ZBH 8.90 USD
  3. Fiscal year 2018: ZBH −1.86 USD
  4. Fiscal year 2019: ZBH 5.47 USD
  5. Fiscal year 2020: ZBH −0.67 USD
  6. Fiscal year 2021: ZBH 1.91 USD
  7. Fiscal year 2022: ZBH 1.10 USD
  8. Fiscal year 2023: ZBH 4.88 USD
  9. Fiscal year 2024: ZBH 4.43 USD
  10. Fiscal year 2025: ZBH 3.55 USD

Revenue

Revenue rose in 5 years from 7.0B USD to 8.2B USD.

ZBH in USD
  1. Fiscal year 2016: ZBH 7.7B USD
  2. Fiscal year 2017: ZBH 7.8B USD
  3. Fiscal year 2018: ZBH 7.9B USD
  4. Fiscal year 2019: ZBH 8.0B USD
  5. Fiscal year 2020: ZBH 7.0B USD
  6. Fiscal year 2021: ZBH 7.8B USD
  7. Fiscal year 2022: ZBH 6.9B USD
  8. Fiscal year 2023: ZBH 7.4B USD
  9. Fiscal year 2024: ZBH 7.7B USD
  10. Fiscal year 2025: ZBH 8.2B USD

Net margin

The net margin rose in 5 years from −2.0% to 8.6%.

ZBH Sector today 13.2% Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.
  1. Fiscal year 2016: ZBH 4.0%
  2. Fiscal year 2017: ZBH 23.2%
  3. Fiscal year 2018: ZBH −4.8%
  4. Fiscal year 2019: ZBH 14.2%
  5. Fiscal year 2020: ZBH −2.0%
  6. Fiscal year 2021: ZBH 5.1%
  7. Fiscal year 2022: ZBH 3.3%
  8. Fiscal year 2023: ZBH 13.8%
  9. Fiscal year 2024: ZBH 11.8%
  10. Fiscal year 2025: ZBH 8.6% · Sector today 13.2%

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 7.7x.

Years without a cut
at least 10
as far as the data goes
Growth per year (5 yrs)
0.0%
dividend per share, average per year
Coverage by free cash flow
7.7x
covered from 1.0x

You can see the dividend yield and shareholder yield (based on the price) with a free account. Sign up free

More depth

Calculation

  • Dividend per share: fiscal year 2020 0.96 USD → fiscal year 2025 0.96 USD = 0.0% per year
  • Free cash flow per share 7.41 USD ÷ dividend per share 0.96 USD = 7.7x

Years without a cut: in a row up to fiscal year 2025, dividend per share according to the SEC, adjusted for stock splits; only 1% less than the year before counts as a cut, also for variable dividends; a special dividend in the prior year does not. If the dividend per share falls while the total paid rises, the run ends as “unclear”. “At least” is shown only if our data ends earlier.

Shareholder yield: dividends paid plus share repurchases minus proceeds from new shares according to the cash flow statement of the last fiscal year, divided by today’s market value. Missing repurchases or new shares count as 0; without reported dividend or repurchase payments (among others for many stocks of the extended selection) there is no value. Describes the reported figures – not investment advice.

History, payout ratios and returns per year

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

The P/E is below its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
0.96 USD · Fiscal year 2025
Dividend growth per year
3 y 0.0%5 y 0.0%10 y +0.9%
Payout ratio
of earnings 27% of free cash flow 13%
To shareholders (5 years)
3.2B USD 69% through repurchases
Share count over 5 years
−4.0% fewer shares – each share is a larger stake

Dividend per share

The dividend per share stayed roughly the same in 5 years (0.96 USD).

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share 0.96 USD
  2. Fiscal year 2017: Dividend per share 0.96 USD
  3. Fiscal year 2018: Dividend per share 0.96 USD
  4. Fiscal year 2019: Dividend per share 0.96 USD
  5. Fiscal year 2020: Dividend per share 0.96 USD
  6. Fiscal year 2021: Dividend per share 0.96 USD
  7. Fiscal year 2022: Dividend per share 0.96 USD
  8. Fiscal year 2023: Dividend per share 0.96 USD
  9. Fiscal year 2024: Dividend per share 0.96 USD
  10. Fiscal year 2025: Dividend per share 0.96 USD

Payout ratios

The payout ratio fell in 4 years from 50.3% to 27.0%.

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2016: Payout ratio (earnings) 63.6% · Payout ratio (free cash flow) 13.0%
  2. Fiscal year 2017: Payout ratio (earnings) 10.8% · Payout ratio (free cash flow) 13.6%
  3. Fiscal year 2018: Payout ratio (earnings) not available · Payout ratio (free cash flow) 12.3%
  4. Fiscal year 2019: Payout ratio (earnings) 17.6% · Payout ratio (free cash flow) 14.3%
  5. Fiscal year 2020: Payout ratio (earnings) not available · Payout ratio (free cash flow) 18.3%
  6. Fiscal year 2021: Payout ratio (earnings) 50.3% · Payout ratio (free cash flow) 15.1%
  7. Fiscal year 2022: Payout ratio (earnings) 87.3% · Payout ratio (free cash flow) 17.2%
  8. Fiscal year 2023: Payout ratio (earnings) 19.7% · Payout ratio (free cash flow) 15.6%
  9. Fiscal year 2024: Payout ratio (earnings) 21.7% · Payout ratio (free cash flow) 15.1%
  10. Fiscal year 2025: Payout ratio (earnings) 27.0% · Payout ratio (free cash flow) 12.9%

What goes back to shareholders

Over 5 years, 3.2B USD went back to shareholders, 69% of it through share repurchases. That is 48% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid 188.4M USD · Share repurchases 415.5M USD · New shares issued (including employee plans) not available · Free cash flow 1.4B USD
  2. Fiscal year 2017: Dividends paid 193.6M USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 1.4B USD
  3. Fiscal year 2018: Dividends paid 195.2M USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 1.6B USD
  4. Fiscal year 2019: Dividends paid 196.7M USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 1.4B USD
  5. Fiscal year 2020: Dividends paid 198.5M USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 1.1B USD
  6. Fiscal year 2021: Dividends paid 200.1M USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 1.3B USD
  7. Fiscal year 2022: Dividends paid 201.2M USD · Share repurchases 126.4M USD · New shares issued (including employee plans) not available · Free cash flow 1.2B USD
  8. Fiscal year 2023: Dividends paid 200.9M USD · Share repurchases 692.2M USD · New shares issued (including employee plans) not available · Free cash flow 1.3B USD
  9. Fiscal year 2024: Dividends paid 196.0M USD · Share repurchases 868.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.3B USD
  10. Fiscal year 2025: Dividends paid 190.3M USD · Share repurchases 487.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.5B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Zimmer Biomet next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison ZBH, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
MDT Medtronic 36.4B USD +3.8%65.0%17.8%13.2%9.7%53.2%14.9%7/9
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
ZBH Zimmer Biomet this stock 8.2B USD +3.2%69.7%13.3%8.6%5.6%55.0%17.9%6/9
MRNA Moderna 1.9B USD +19.3%55.3%−158.1%−145.2%−32.6%70.1%−106.2%2/9
Median of the sector 27 symbols 44.3B USD +8.4%67.9%17.8%13.2%13.6%38.5%15.8%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector ZBH next to ISRG – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+3.2% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 3.2% per year on average, but more slowly than the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light gray: not computable

– per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: not computable (loss in the first or last year)

What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

8.6% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 8.57 USD remained as profit – less than the median company in the sector (13.9%). Five years ago the margin was −2.0%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light green: lower than sector

0.49 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 0.49 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

27% Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.27 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 56%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light red: 2 loss years

8 of 10 fiscal years with a profit

What does this mean? In 8 of the last 10 fiscal years the bottom line showed a profit. 2 years ended with a loss.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
8.2B USD
Revenue vs. prior year
+7.2%
Net income (FY)
705.1M USD
Net income vs. prior year
−22.0%
EPS (FY)
3.55 USD
Superinvestors holding
3 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 20, 2026 · Balance sheet Sep 30, 2026 (filed Nov 4, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 8.2B705.1M 8.6% 3.55 0.96 27%
2024Dec 31, 2024 7.7B903.8M 11.8% 4.43 0.96 22%
2023Dec 31, 2023 7.4B1.0B 13.8% 4.88 0.96 20%
2022Dec 31, 2022 6.9B231.4M 3.3% 1.10 0.96 87%
2021Dec 31, 2021 7.8B401.6M 5.1% 1.91 0.96 50%
2020Dec 31, 2020 7.0B−138.9M −2.0% −0.67 0.96 –
2019Dec 31, 2019 8.0B1.1B 14.2% 5.47 0.96 18%
2018Dec 31, 2018 7.9B−379.2M −4.8% −1.86 0.96 –
2017Dec 31, 2017 7.8B1.8B 23.2% 8.90 0.96 11%
2016Dec 31, 2016 7.7B305.9M 4.0% 1.51 0.96 64%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 2.1B191.6M 9.3% 1.00 0.24 24%
Q2/26Jun 30, 2026 2.2B198.3M 9.1% 1.03 0.24 23%
Q1/26Mar 31, 2026 2.1B238.1M 11.4% 1.22 0.24 20%
Q4/25*Dec 31, 2025 2.2B139.3M 6.2% – 0.24 –
Q3/25Sep 30, 2025 2.0B230.9M 11.5% 1.16 0.24 21%
Q2/25Jun 30, 2025 2.1B152.8M 7.4% 0.77 0.24 31%
Q1/25Mar 31, 2025 1.9B182.0M 9.5% 0.91 0.24 26%
Q4/24*Dec 31, 2024 2.0B239.5M 11.8% – 0.24 –
Q3/24Sep 30, 2024 1.8B249.1M 13.7% 1.23 0.24 20%
Q2/24Jun 30, 2024 1.9B242.8M 12.5% 1.18 0.24 20%
Q1/24Mar 31, 2024 1.9B172.4M 9.1% 0.84 0.24 29%
Q4/23*Dec 31, 2023 1.9B419.2M 21.6% – 0.24 –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $824.0K2 people −$824.0K
6 months $00 people $1.2M3 people −$1.2M
12 months $00 people $1.6M4 people −$1.6M

Latest transactions

  • Sep 11, 2026 Thornal Kevin R Officer Open-market sale 5,691 shares · $529.0K · SEC
  • Sep 4, 2026 Phipps Chad F Officer Open-market sale 3,000 shares · $295.1K · SEC
  • May 29, 2026 Yi Sang Officer Open-market sale 800 shares · $66.1K · SEC
  • May 29, 2026 Yi Sang Officer Open-market sale 4,200 shares · $347.1K · SEC
  • Mar 12, 2026 Winkler Lori Officer Open-market sale 2,650 shares · $250.8K · SEC
  • Feb 12, 2026 Yi Sang Officer Open-market sale 1,000 shares · $96.5K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Zimmer Biomet?

All superinvestor portfolios

3 of 26 tracked superinvestors report a position.

Superinvestors with a position in Zimmer Biomet, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Steve Cohen Point72 Asset Management < 0.1% −38.8% reduced Q3 2026
Bridgewater Associates < 0.1% +64.1% increased Q3 2026
Renaissance Technologies < 0.1% new Q3 2026

Sold out in the latest quarter: Paul Tudor Jones.

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on ZBH yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: ZBH

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close